Dabrafenib

Definition

An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

Also known as Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-, BRAF Inhibitor GSK2118436, DABRAFENIB, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A — per NCIT

Also identified as

• ATC L01EC02 per RXNORM
• NCIT NCIT:C82386 per NCIT
• SCTID 703641001 per RXNORM
• SCTID 703646006 per RXNORM
• UNII QGP4HA4G1B per RXNORM

Indications